Given that current standards of care for diseases characterized by aberrant angiogenesis such as neovascular age-related macular degeneration and diabetic retinopathy often lose efficacy over time [59], therapeutic targeting of IRE1α may provide additional benefits. Here, ERN1 is linked to diabetic retinopathy.